Skip to main content

German Federal Joint Committee (G-BA)

21
Mar 2019

Updates about screening programs in Germany

During November-December 2018, the Federal Joint Committee (G-BA) has introduced an organized screening program for the early detection of cervical cancer and initiated consultation procedure for prostate cancer screening.
14
Sep 2018

The discussion regarding the establishment of the minimum quantity requirements for the surgical treatment of lung and breast cancer was initiated by the Federal Joint Committee (G-BA) in July of 2018

In July of 2018, the Federal Joint Committee (G-BA) has initiated the discussion regarding the establishment of the minimum quantity requirements for the surgical treatment of breast cancer and bronchial carcinoma. As the quality of surgery is directly dependent on the quantity, the number of operations performed at hospital and on the designated surgeon, the objective is to understand the importance of the experience and routine practice of the operations to reach the successful treatment outcomes and to determine a minimum number of operations, which should be performed in hospitals to gain enough experience.
11
Sep 2018

The update of Disease Management Program for Diabetes Mellitus type 2 was commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) at the end of June of 2018

At the end of June of 2018, the Federal Joint Committee (G-BA) has commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) to provide an update of the Disease Management Program (DMP) for Diabetes Mellitus type 2 in order to perform a systematic research, make a selection of guidelines based on methodological criteria and extract guideline recommendations relevant for the treatment of Diabetes Mellitus type 2. The final report is expected to be released on the 31st of December, 2019.
23
Aug 2018

The further evaluation of biomarker-based tests in primary breast cancer was commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) at the beginning of July of 2018

At the beginning of July of 2018, the Federal Joint Committee (G-BA) has commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) to provide an assessment of potential harm and benefits of biomarker-based tests for or against adjuvant chemotherapy in primary breast to understand its efficacy in comparison with the previous standard examinations in women who do not require chemotherapy due to a low/intermediate risk of relapse. The final report is expected to be released by G-BA at the end of 2018.
03
Jul 2018

The Institute for Quality and Efficiency in Health Care (IQWiG) has published the rapid report for osteoporosis disease management program in April of 2018

In April of 2018, the Institute for Quality and Efficiency in Health Care (IQWiG) has published an update for the report V14-03 “Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a disease management program (DMP) for osteoporosis” from 2016 in order to find additional evidence on integrated concepts of medical and physical rehabilitation. However, no new information was identified and included into the report.
22
Jun 2018

The Institute for Quality and Efficiency in Health Care (IQWiG) has published an update to the report for colorectal cancer screening in persons with familial risk in May of 2018

On the 23rd of May of 2018, the Institute for Quality and Efficiency in Health Care (IQWiG) has published an update version of the report “Colorectal cancer screening in persons with familial risk”, which was commissioned to IQWiG by the Federal Joint Committee (G-BA) in October of 2017 to provide an answer, whether people under 55 years of age with a family history of colorectal cancer benefit from a screening test. Like the previous report, the current one therefore concluded that the benefit of screening for under 55-year-olds with a family history of colorectal cancer is unclear.
07
Jun 2018

Two additional indications for application of positron emission tomography (PET)/computed tomography (CT) in malignant lymphomas was approved by the Federal Joint Committee (G-BA) in May of 2018

In May of 2018, the Federal Joint Committee (G-BA) approved two additional indications for application of PET/CT for management of malignant lymphomas for coverage within statutory health insurance. As the procedures were included into Directive for methods and examinations and Directive methods of the contract medical care, they are now reimbursed in both hospital and out-patient settings.
01
Jun 2018

The Institute for Quality and Efficiency in Health Care (IQWiG) has published the addendum to the report for the ultrasound-guided high-focused ultrasound therapy for malignant neoplasms of the pancreas at the beginning of May of 2018

On the 9th of May of 2018, the addendum H18-01 to the report H16-02C “Ultrasound-guided high-focused ultrasound (USgHIFU) therapy for malignant neoplasms of the pancreas” commissioned by the Federal Joint Committee (G-BA) at the beginning of March of 2018, was published by the Institute for Quality and Efficiency in Health Care (IQWiG) on its web-site.
25
May 2018

The call for a tender to conduct a pilot study “Transcorneal Electrical Stimulation in Retinitis Pigmentosa” was announced by the Federal Joint Committee (G-BA) at the end of April of 2018

On the 26th of April of 2018, the Federal Joint Committee (G-BA) has announced the call for a tender for the pilot study “Transcorneal Electrical Stimulation in Retinitis Pigmentosa” in the Official Journal of the European Union. The deadline for the requests is the 22nd of June, 2018, 14:00
23
May 2018

The assessment of current medical knowledge on synchronous balneophototherapy in atopic eczema was commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) in April of 2018

On the 26th of April of 2018, the Federal Joint Committee (G-BA) has commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) to provide a rapid report regarding the current state of medical knowledge on synchronous balneophototherapy in atopic eczema. The identified results of the current state of medical knowledge would form the basis for the further G-BA’s assessment of adequacy, appropriateness and economic benefits of the researched method.